



14981 3624

Patent Docket P1981R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Frederic J. DeSauvage et al. Serial No.: 10/526,806 Filed: March 4, 2005 For: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR	Group Art Unit: 3624 Examiner: NOT KNOWN Confirmation No: 9927 CUSTOMER NO: 09157
	<p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on</p> <p>September 8, 2006</p> <p><i>Aida Guiam</i> Aida Guiam</p>

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR § 1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

37 CFR §1.97(c)

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

37 CFR §1.97(d)

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- 37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- 37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR §1.98(a)(2)(ii)]. See Final Rule 1287 OG (October 12, 2004). Other documents cited with an asterisk have not been supplied because they were previously cited by or submitted to the Office in prior application Serial No. , filed and benefit from the prior application is claimed in this

application under 35 U.S.C §120. However, copies of any cited document will be provided in its entirety at the request of the Office.

A concise explanation of relevance of the items listed on PTO-1449 is:

- not given
- given for each listed item
- given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).


The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
GENENTECH, INC.

Date: September 8, 2006

By: _____
Atulya R. Agarwal, Ph.D.
Reg. No. 40,887
Telephone No. (650)

1 DNA Way
So. San Francisco, CA 94080-4990
Facsimile No.: (650) 952-9881



<p>FORM PTO-1449 SEP 12 2006</p> <p>LIST OF DISCLOSURES CITED BY APPLICANT</p> <p>(Use several sheets if necessary)</p>					<p>U.S. Dept. of Commerce Patent and Trademark Office</p>		<p>Atty Docket No. P1981R1</p>		<p>Serial No. 10/526,806</p>	
					<p>Applicant Frederic J. DeSauvage et al.</p>					
					<p>Filing Date 04 Mar 2005</p>		<p>Group 3624</p>			
U.S. PATENT DOCUMENTS										
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date			
	8	2002/0049180 A1	25.04.02	Wu Bin et al.						
FOREIGN PATENT DOCUMENTS										
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No			
	9	WO 01/91739 A2	06.12.01	PCT						
	10	WO 99/65928	23.12.99	PCT						
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)										
11		Heyer, B.S. et al., "New member of the SNF1/AMPK kinase family, MELK, is expressed in the mouse egg and preimplantation embryo" <u>Mol. Reprod. and Development</u> 47(2):148-156 (1997)								
12		Nagase et al., "Prediction of the Coding Sequences of Unidentified Human Genes. V. The Coding Sequences of 40 New Genes (KIAA0161-KIAA0200) Deduced by Analysis of cDNA Clones from Human Cell Line KG-1" <u>DNA Research</u> 3(1):17-24 (1996)								
13		Plowman et al., "Human protein kinase #9" <u>Database Geneseq</u> (Derwent, London, UK) Accession No. AAU035509 (WO200138503-A2, 31 May 2001, 99.5% identical to SEQ ID NO: 4)								
14		Wu et al., "New isolated specific inhibitor useful for decreasing the expression of the inhibitor in a mammalian cell" <u>Database Geneseq</u> (Derwent, London, UK, Accession No. AAI72250 (2001WO-US017644, 06 Dec 2001, 100% identical to SEQ ID NO: 1)								
Examiner					Date Considered					
<p>Examiner: initial if reference considered, whether or not citation is in conformance with MPEL 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										

Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.